Topics

Articles

Drug Wholesalers and the Generic Price War

Newly Formed Standards Charter Organization (SCO) Lays Foundation for National HIT Agenda

Could proposed legislation undercut the promise of targeted therapies?

The stakes are high in the debate over follow-on biologics

Claims of the death of the pharma sales rep occupation have been greatly exaggerated

In Defense of Sales Reps

Bipartisan group of senators sponsor a revived drug-importation bill

Here We Go Again on 'Re-Importation'

Pharma 2020: Marketing the Future

The studio model: how film industry practices can boost pharmaceutical creativity

A New Business Model for Pharma Innovation

FDA’s management of drug and device safety enters GAO’s biennial watch list

No surprise here: FDA drug oversight is now a 'high risk' government operation

It has been said that one should never miss an opportunity to make the most of a crisis. The steady stream of headlines announcing staff cuts, delays in drug approvals and a narrowing of R&D focus for pharmaceutical and biotech companies indicate there will be no shortage of opportunities in 2009.

Leading in Challenging Times

‘Ultra-orphan’ diseases will alter the specialty distribution process

Opinion